clarithromycin

clarithromycin is a lipid of Polyketides (PK) class. Clarithromycin is associated with abnormalities such as Helicobacter Pylori Infection, Infection, Coinfection, Gastritis and Peptic Ulcer. The involved functions are known as Point Mutation, Increased Sensitivy, Bacterial resistance, urease activity and Mutation. Clarithromycin often locates in Blood, Gastric mucosa, Biopsy sample, Respiratory System and Entire gastrointestinal tract. The associated genes with clarithromycin are Genes, rRNA, rRNA Operon, Genome, HM13 gene and GDF15 gene. The related lipids are 9,11-linoleic acid, Steroids, Lysophosphatidylcholines, Lipopolysaccharides and 4-hydroxycholesterol. The related experimental models are Mouse Model, Knock-out and Experimental Pneumococcal Meningitis.

Cross Reference

Introduction

To understand associated biological information of clarithromycin, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.

What diseases are associated with clarithromycin?

clarithromycin is suspected in Infection, Helicobacter Pylori Infection, Pneumonia, Respiratory Tract Infections, PARKINSON DISEASE, LATE-ONSET, Community acquired pneumonia and other diseases in descending order of the highest number of associated sentences.

Related references are mostly published in these journals:

Disease Cross reference Weighted score Related literature
Loading... please refresh the page if content is not showing up.

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with clarithromycin

MeSH term MeSH ID Detail
Infant, Premature, Diseases D007235 7 associated lipids
Parkinson Disease D010300 53 associated lipids
Monoclonal Gammopathy of Undetermined Significance D008998 2 associated lipids
Influenza, Human D007251 11 associated lipids
Lymphadenitis D008199 8 associated lipids
Drug Eruptions D003875 30 associated lipids
Skin Diseases, Infectious D012874 7 associated lipids
Eye Infections, Bacterial D015818 3 associated lipids
Synovitis D013585 15 associated lipids
Peptic Ulcer Perforation D010439 3 associated lipids
Carcinoma, Lewis Lung D018827 22 associated lipids
Renal Insufficiency D051437 8 associated lipids
Ventricular Dysfunction, Left D018487 33 associated lipids
Genetic Predisposition to Disease D020022 24 associated lipids
Plaque, Atherosclerotic D058226 7 associated lipids
Insulin Resistance D007333 99 associated lipids
Liver Failure, Acute D017114 11 associated lipids
Periodontal Attachment Loss D017622 7 associated lipids
Bacteremia D016470 9 associated lipids
Hemophilia A D006467 10 associated lipids
Encephalitis D004660 15 associated lipids
Barrett Esophagus D001471 3 associated lipids
Rhabdomyolysis D012206 9 associated lipids
Gingival Overgrowth D019214 7 associated lipids
Meningitis, Bacterial D016920 6 associated lipids
Actinomycetales Infections D000193 4 associated lipids
Pneumonia, Bacterial D018410 16 associated lipids
Rosacea D012393 13 associated lipids
Psychoses, Substance-Induced D011605 7 associated lipids
Neurotoxicity Syndromes D020258 34 associated lipids
Abortion, Spontaneous D000022 12 associated lipids
Esophagitis, Peptic D004942 4 associated lipids
Helicobacter Infections D016481 21 associated lipids
Dermatitis, Phototoxic D017484 4 associated lipids
Keratoconjunctivitis D007637 3 associated lipids
Gastroesophageal Reflux D005764 10 associated lipids
Community-Acquired Infections D017714 8 associated lipids
Mycobacterium avium-intracellulare Infection D015270 4 associated lipids
Hand Dermatoses D006229 5 associated lipids
Gastritis, Atrophic D005757 4 associated lipids
Ergotism D004881 4 associated lipids
Ecchymosis D004438 3 associated lipids
AIDS-Related Opportunistic Infections D017088 9 associated lipids
Psychophysiologic Disorders D011602 3 associated lipids
Dyspepsia D004415 5 associated lipids
Skin Diseases, Bacterial D017192 8 associated lipids
Giardiasis D005873 3 associated lipids
Common Variable Immunodeficiency D017074 4 associated lipids
Purpura, Thrombocytopenic, Idiopathic D016553 4 associated lipids
Peptic Ulcer Hemorrhage D010438 4 associated lipids
Eye Injuries, Penetrating D015807 2 associated lipids
Prurigo D011536 4 associated lipids
Chlamydia Infections D002690 7 associated lipids
Legionnaires' Disease D007877 4 associated lipids
Whooping Cough D014917 6 associated lipids
Urethritis D014526 9 associated lipids
Boutonneuse Fever D001907 5 associated lipids
Fistula D005402 8 associated lipids
Dermatitis, Exfoliative D003873 10 associated lipids
Confusion D003221 4 associated lipids
Uveitis, Anterior D014606 11 associated lipids
Chromoblastomycosis D002862 2 associated lipids
Soft Tissue Injuries D017695 2 associated lipids
Lymphoma, T-Cell, Cutaneous D016410 4 associated lipids
Bronchiectasis D001987 7 associated lipids
Bronchiolitis Obliterans D001989 8 associated lipids
Parotitis D010309 4 associated lipids
Iris Diseases D007499 2 associated lipids
Exanthema D005076 11 associated lipids
Bronchiolitis D001988 6 associated lipids
Conjunctival Neoplasms D003230 3 associated lipids
Chlamydophila Infections D023521 4 associated lipids
Ureteral Diseases D014515 3 associated lipids
IgA Deficiency D017098 2 associated lipids
Cryptogenic Organizing Pneumonia D018549 3 associated lipids
Ureaplasma Infections D016869 5 associated lipids
Erythema Nodosum D004893 5 associated lipids
Soft Tissue Infections D018461 2 associated lipids
alpha 1-Antitrypsin Deficiency D019896 3 associated lipids
Pleuropneumonia D011001 3 associated lipids
Cytomegalovirus Retinitis D017726 2 associated lipids
Still's Disease, Adult-Onset D016706 2 associated lipids
Leprosy, Borderline D015439 3 associated lipids
Discitis D015299 2 associated lipids
Cardiovascular Abnormalities D018376 2 associated lipids
Pneumonia, Mycoplasma D011019 6 associated lipids
Desulfovibrionaceae Infections D045824 5 associated lipids
Periodontal Abscess D010508 2 associated lipids
Sexually Transmitted Diseases, Bacterial D015231 5 associated lipids
Conjunctivitis, Bacterial D003234 3 associated lipids
Psittacosis D009956 4 associated lipids
Angiomatosis, Bacillary D016917 2 associated lipids
Mycetoma D008271 4 associated lipids
Diphtheria D004165 2 associated lipids
Empyema D004653 3 associated lipids
Rickettsia Infections D012282 5 associated lipids
Sporotrichosis D013174 3 associated lipids
Pleural Diseases D010995 4 associated lipids
Bartonella Infections D001474 3 associated lipids
Lymphangitis D008205 4 associated lipids
Per page 10 20 50 100 | Total 242

PubChem Associated disorders and diseases

What pathways are associated with clarithromycin

There are no associated biomedical information in the current reference collection.

PubChem Biomolecular Interactions and Pathways

Link to PubChem Biomolecular Interactions and Pathways

What cellular locations are associated with clarithromycin?

Related references are published most in these journals:

Location Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What functions are associated with clarithromycin?


Related references are published most in these journals:

Function Cross reference Weighted score Related literatures

What lipids are associated with clarithromycin?

Related references are published most in these journals:

Lipid concept Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

What genes are associated with clarithromycin?

Related references are published most in these journals:


Gene Cross reference Weighted score Related literatures

What common seen animal models are associated with clarithromycin?

Mouse Model

Mouse Model are used in the study 'Inflammation provoked by Mycoplasma pneumoniae extract: implications for combination treatment with clarithromycin and dexamethasone.' (Hirao S et al., 2011), Mouse Model are used in the study 'Tolerance and pharmacokinetic interactions of rifabutin and clarithromycin in human immunodeficiency virus-infected volunteers.' (Hafner R et al., 1998), Mouse Model are used in the study 'Clarithromycin attenuates mastectomy-induced acute inflammatory response.' (Chow LW et al., 2000) and Mouse Model are used in the study 'In vitro and in vivo influence of adjunct clarithromycin on the treatment of mucoid Pseudomonas aeruginosa.' (Bui KQ et al., 2000).

Knock-out

Knock-out are used in the study 'Intrinsic macrolide resistance in Mycobacterium smegmatis is conferred by a novel erm gene, erm(38).' (Nash KA, 2003).

Experimental Pneumococcal Meningitis

Experimental Pneumococcal Meningitis are used in the study 'Failure of treatment for chronic Mycobacterium abscessus meningitis despite adequate clarithromycin levels in cerebrospinal fluid.' (Maniu CV et al., 2001).

Related references are published most in these journals:

Model Cross reference Weighted score Related literatures
Loading... please refresh the page if content is not showing up.

NCBI Entrez Crosslinks

All references with clarithromycin

Download all related citations
Per page 10 20 50 100 | Total 7636
Authors Title Published Journal PubMed Link
Hung IFN et al. Efficacy of Clarithromycin-Naproxen-Oseltamivir Combination in the Treatment of Patients Hospitalized for Influenza A(H3N2) Infection: An Open-label Randomized, Controlled, Phase IIb/III Trial. 2017 Chest pmid:27884765
Ozturk O et al. Therapeutic success with bismuth-containing sequential and quadruple regimens in Helicobacter pylori eradication. 2017 Arab J Gastroenterol pmid:28601610
Aguilera-Correa JJ et al. Detection of Helicobacter pylori and the genotypes of resistance to clarithromycin and the heterogeneous genotype to this antibiotic in biopsies obtained from symptomatic children. 2017 Diagn. Microbiol. Infect. Dis. pmid:27863951
Alirezaei A et al. Helicobacter pylori Eradication With Levofloxacin or Clarithromycin in Dialysis Versus Nonuremic Patients. 2017 Iran J Kidney Dis pmid:28575885
Katayama Y et al. Neuroprotective effects of clarithromycin against neuronal damage in cerebral ischemia and in cultured neuronal cells after oxygen-glucose deprivation. 2017 Life Sci. pmid:27825902
Cosme A et al. Antimicrobial susceptibility testing before first-line treatment for infection in patients with dual or triple antibiotic resistance. 2017 World J. Gastroenterol. pmid:28566898
Moj D et al. Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens. 2017 AAPS J pmid:27822600
Angol DC et al. from Peptic Ulcer Patients in Uganda Is Highly Resistant to Clarithromycin and Fluoroquinolones: Results of the GenoType HelicoDR Test Directly Applied on Stool. 2017 Biomed Res Int pmid:28555193
Akpinar Z et al. Improving the standard sequential treatment of Helicobacter pylori with either extended treatment or by adding bismuth. 2017 Arab J Gastroenterol pmid:28532623
Beckman E et al. A Novel Stool PCR Test for Helicobacter pylori May Predict Clarithromycin Resistance and Eradication of Infection at a High Rate. 2017 J. Clin. Microbiol. pmid:28515219
Kajihara Y et al. Analysis of the cost-effectiveness of using vonoprazan-amoxicillin-clarithromycin triple therapy for first-line Helicobacter pylori eradication. 2017 Scand. J. Gastroenterol. pmid:27806639
Yan J et al. Survey about the use of clarithromycin in an ENT outpatient department of a tertiary hospital. 2017 Eur Arch Otorhinolaryngol pmid:28508178
DaCosta A et al. Outcomes associated with antibiotic regimens for treatment of Mycobacterium abscessus in cystic fibrosis patients. 2017 J. Cyst. Fibros. pmid:28495380
Sharifi R et al. Dietary PUFA Increase Apoptosis in Stomach of Patients with Dyspeptic Symptoms and Infected with H. pylori. 2017 Lipids pmid:28493185
Ivanová L et al. Estimation of amount of selected pharmaceuticals sorbed onto digested sludge from wastewater treatment plant Bratislava-Petržalka. 2017 Environ. Res. pmid:28183039
Giguère S et al. Antimicrobial Resistance in . 2017 Microbiol Spectr pmid:29052538
Varma MV et al. Transporter-Mediated Hepatic Uptake Plays an Important Role in the Pharmacokinetics and Drug-Drug Interactions of Montelukast. 2017 Clin. Pharmacol. Ther. pmid:27648490
Huet D et al. [Pulmonary infection with Mycobacterium malmoense. Difficulties in diagnosis and treatment]. 2017 Rev Mal Respir pmid:27639948
El Haj C et al. The anti-biofilm effect of macrolides in a rat model of S. aureus foreign-body infection: Might it be of clinical relevance? 2017 Med. Microbiol. Immunol. pmid:27639707
Jia L et al. Synthesis and antibacterial evaluation of novel 11-O-carbamoyl clarithromycin ketolides. 2017 Bioorg. Med. Chem. Lett. pmid:28711353
Seyama S et al. Emergence and molecular characterization of Haemophilus influenzae harbouring mef(A). 2017 J. Antimicrob. Chemother. pmid:27999037
Zerbetto De Palma G et al. Occurrence of Mutations in the Antimicrobial Target Genes Related to Levofloxacin, Clarithromycin, and Amoxicillin Resistance in Helicobacter pylori Isolates from Buenos Aires City. 2017 Microb. Drug Resist. pmid:27391421
Giguère S Treatment of Infections Caused by Rhodococcus equi. 2017 Vet. Clin. North Am. Equine Pract. pmid:28161038
Berni E et al. Risk of cardiovascular events, arrhythmia and all-cause mortality associated with clarithromycin versus alternative antibiotics prescribed for respiratory tract infections: a retrospective cohort study. 2017 BMJ Open pmid:28115334
Serrano CA et al. Helicobacter pylori-Clarithromycin Resistance in Symptomatic Pediatric Patients in a High Prevalence Country. 2017 J. Pediatr. Gastroenterol. Nutr. pmid:27159208
Yatera K et al. The additive effect of clarithromycin on influenza A infection in the elderly patients and patients with comorbid diseases. 2017 Respir Investig pmid:29153420
Lee MC et al. Antimicrobial resistance in Mycobacterium abscessus complex isolated from patients with skin and soft tissue infections at a tertiary teaching hospital in Taiwan. 2017 J. Antimicrob. Chemother. pmid:29091186
Laidler N Cutaneous infection with paucibacillary treated successfully with a modified antituberculous drug regimen. 2017 BMJ Case Rep pmid:29275384
Lee JS et al. Implication of species change of Nontuberculous Mycobacteria during or after treatment. 2017 BMC Pulm Med pmid:29262802
Chen MJ et al. Impact of amoxicillin resistance on the efficacy of amoxicillin-containing regimens for Helicobacter pylori eradication: analysis of five randomized trials. 2017 J. Antimicrob. Chemother. pmid:28961996
Kim SY et al. Helicobacter pylori eradication rates of concomitant and sequential therapies in Korea. 2017 Helicobacter pmid:28940815
Mukherjee D et al. Vancomycin and Clarithromycin Show Synergy against . 2017 Antimicrob. Agents Chemother. pmid:28923867
Tsay FW et al. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance. 2017 Antimicrob. Agents Chemother. pmid:28807915
Oh ES et al. Effects of clarithromycin on the pharmacokinetics of evogliptin in healthy volunteers. 2017 J Clin Pharm Ther pmid:28806472
Kuo YT et al. Primary antibiotic resistance in Helicobacter pylori in the Asia-Pacific region: a systematic review and meta-analysis. 2017 Lancet Gastroenterol Hepatol pmid:28781119
Ramas M et al. Efficacy and safety of rifaximin associated with standard triple therapy (omeprazole, clarithromycin and amoxicillin) for H. pylori eradication: A phase IV pilot clinical trial. 2017 Gastroenterol Hepatol pmid:28780968
Lin CM et al. Is ionizing radiation a risk factor to diffuse panbronchiolitis? 2017 QJM pmid:28069906
Tanabe H et al. Efficacy of Vonoprazan-Based Triple Therapy for Helicobacter pylori Eradication: A Multicenter Study and a Review of the Literature. 2017 Dig. Dis. Sci. pmid:28664410
Sue S et al. The Superiority of Vonoprazan-based First-line Triple Therapy with Clarithromycin: A Prospective Multi-center Cohort Study on Helicobacter pylori Eradication. 2017 Intern. Med. pmid:28566587
Hu Y et al. Novel and Effective Therapeutic Regimens for in an Era of Increasing Antibiotic Resistance. 2017 Front Cell Infect Microbiol pmid:28529929
Jeong SH et al. Mycobacteriological characteristics and treatment outcomes in extrapulmonary Mycobacterium abscessus complex infections. 2017 Int. J. Infect. Dis. pmid:28522316
Kishida D et al. Intractable Cutaneous Nontuberculous Mycobacteriosis (Mycobacterium abscessus) during Treatment for Systemic Lupus Erythematosus. 2017 Intern. Med. pmid:28502947
Jung YS et al. Systematic review with meta-analysis: the efficacy of vonoprazan-based triple therapy on Helicobacter pylori eradication. 2017 Aliment. Pharmacol. Ther. pmid:28497487
Sharman MJ et al. Gastrokine mRNA expression in gastric tissue from dogs with helicobacter colonisation but without inflammatory change during treatment. 2017 Vet. Immunol. Immunopathol. pmid:28494926
Inukai K et al. Effect of gel formation on the dissolution behavior of clarithromycin tablets. 2017 Int J Pharm pmid:28196716
Miftahussurur M et al. Clarithromycin-Based Triple Therapy is Still Useful as an Initial Treatment for Infection in the Dominican Republic. 2017 Am. J. Trop. Med. Hyg. pmid:28193745
Zhang Z et al. In vitro activity of clarithromycin in combination with other antimicrobial agents against Mycobacterium abscessus and Mycobacterium massiliense. 2017 Int. J. Antimicrob. Agents pmid:28188830
Kristin F et al. Dissolution and dissolution/permeation experiments for predicting systemic exposure following oral administration of the BCS class II drug clarithromycin. 2017 Eur J Pharm Sci pmid:28179133
Chen D et al. Phenotypic and Molecular Antimicrobial Susceptibility of Helicobacter pylori. 2017 Antimicrob. Agents Chemother. pmid:28167563
Olesen JS et al. Mycobacterium chelonae hand infection after steroid injection in a patient with rheumatoid arthritis receiving long-term linezolid therapy. 2017 BMJ Case Rep pmid:28137898